Figures cited from published bioaccess® pages are as of July 2026 unless noted. General information, not tax, legal, or regulatory advice. Confirm current rules with qualified advisers.
If you typed Mobius CRO, Mobius Medical CRO, or Australia EFS CRO into Google or an AI box, the real question is operational: should this first-in-human or early-feasibility device study start in Australia and New Zealand, or in Latin America with a U.S.-anchored specialist?
Mobius Medical (mobius-cro.com) is the Australian device-first boutique that dominates that shortlist. bioaccess® is the First-in-Human CRO — U.S. regulatory anchoring plus Latin American execution. This is a calendar, cash, entity, and evidence-portability comparison, not a teardown. Mobius wins English ANZ continuity and a published mitral-valve EFS-to-pivotal history. bioaccess® wins lower gross cash, Latin American surgical volume, and no Australian company to stand up before first patient in.
What “Mobius CRO” actually is
Mobius is a founder-led, device-first CRO headquartered in North Sydney (Mobius Medical Pty Ltd, Suite 1403, 275 Alfred Street, NSW 2060 on the firm’s privacy notice). The homepage’s “18 years of operational expertise” and the company’s public founding year put the start in 2008. The site lists offices in Australia, New Zealand, and the United States; the U.S. number is a Minneapolis-area line (+1 612-328-9664). Quality is framed as ISO 9001, with “10+ years” of certified QMS.
Live homepage claims, verified 23 August 2026: 140+ successful trials, including 100+ in medical devices, and 27+ therapeutic areas. About-page principals: Stefan Czyniewski (co-founder, CEO ANZ/USA), Suzanne Williams (co-founder, COO), Richard Brookes (CFO), plus David Pomfret (VP Clinical Operations, USA) and Samantha Flynn (Head Clinical Operations, ANZ).
That is a hospital-device CRO, not a healthy-volunteer Phase I unit. If the protocol needs ISO 14155, a local Australian sponsor, HREC plus Clinical Trial Notification (CTN), and an English handoff into a later U.S. study, Mobius is built for it. So are smaller ANZ device shops. Mobius is the one with the most public EFS-to-pivotal story.
The two public device stories
Tendyne TMVR: Australian EFS into a global pivotal
Mobius’s case study Early feasibility to global pivotal trial for mitral valve innovation describes a repositionable TMVR system — Tendyne — that started as an Australian early-feasibility program and expanded under one protocol into a global pivotal. Outcomes they list: durable valve function, improved survival and quality-of-life signals, CE Mark in 2020, FDA approval in 2025. If the board’s question is “has this CRO taken a structural implant from Australian EFS to CE and FDA?”, the public answer is yes.
Bionic Vision: lead sponsor of record
NCT03406416 — a 44-channel fully implantable suprachoroidal retinal prosthesis — lists Mobius Medical Pty Ltd as lead sponsor. Status: completed (13 February 2018–18 December 2020). Collaborators on the record include Bionic Vision Technologies, the Centre for Eye Research Australia, the Bionics Institute, the University of Melbourne, Data 61 CSIRO, and the Australian National University. Four participants at CERA, Melbourne. Named implant FIH, not a logo wall.
Neither story is a reason to default every new EFS to Australia. Both are a reason to take Mobius seriously when the protocol looks like those protocols.
What an Australia EFS CRO is selling
The pitch is consistent on Mobius’s startup and FAQ pages:
- CTN, not a U.S. IDE, to start. No TGA clinical pre-review under notification. Ethics is HREC. Site governance is a second clock.
- ISO 14155 / ICH-GCP data in English for FDA IDE or 510(k). Mobius’s phrase: “ANZ-to-US bridge.”
- Local sponsor for trial conduct — a different problem from rebate eligibility, which still generally wants an eligible Australian company.
- Budget band they publish: full-service early feasibility typically AUD $250,000–$1 million; pivotal higher. Their number, not ours.
- Tax offset. Mobius writes “up to 43% cashback.” bioaccess® publishes the statutory figure on our Australia pages: a 43.5% refundable R&D tax offset for groups under A$20 million aggregated turnover, clinical-trial spend eligible and exempt from the A$4 million refund cap (FY2025–26 and FY2026–27). Model 43.5%. Treat “43%” as marketing rounding.
The mistake is treating the rebate as a 43.5% price cut, and treating CTN as faster than Latin America before you add HREC plus site-by-site governance.
The comparison that hits the runway
The country math is already published. This pillar will not invent a second rebate table. Use bioaccess® vs Australia and The Australian R&D Rebate Math, Honestly. Facts we will not move:
- On a gross, cash-contracting basis, Latin America runs, in bioaccess®’s program experience, about 35–45% below Australia (varies with design and FX).
- A fully captured 43.5% rebate narrows the effective gap to roughly 5–15%. In some programs it can close or reverse the gap.
- Capture is conditional: R&D generally through an eligible Australian company below A$20 million aggregated turnover (counts a U.S. parent). You fund the gross now; cash returns after year-end lodgement. Rebate-advance financing exists and has a cost.
- An R&DTI redesign has been announced (not legislated) for 1 July 2028: refundable-offset threshold to A$50 million, refundability limited to companies under 10 years old. Current-year claims unaffected.
- End-to-end start-up is broadly comparable once Australian site governance is included. Australia: CTN plus typically ~6–8 weeks HREC plus site governance. Latin America example already on those pages: Argentina ANMAT Disposition 7516/2025 (Annex III) caps Phase I / non-low-risk review at ~35 technical + 10 administrative business days (≈45), ~30 for low-risk, ethics in parallel (queries pause the clock).
Mobius’s AUD $250k–$1M band is an Australia planning envelope. It is not a Latin America quote and it is not net of rebate. Subtracting 43.5% before you have an ABN, AusIndustry registration, and cash to fund the gross is modeling a company you have not formed.
Entity, calendar, distance, volume
Four frictions decide most Mobius-versus-Latin-America meetings. No unpublished median day-count.
Entity
Mobius can be local sponsor and run HREC/CTN. That is trial conduct. It is not automatically rebate eligibility. A three-to-five-person U.S. team that wants 43.5% still generally forms an Australian company and pays advisers. bioaccess® contracts and starts in Latin America with no foreign subsidiary. If the rebate is how the round was sold and counsel will form the entity, Australia can win. If the entity is unscoped, the rebate is not in the cash forecast.
Calendar: CTN/HREC vs INVIMA/ANVISA
CTN is fast to notify. The clocks that slip are HREC and hospital governance. Latin America is not one clock: Brazil (ANVISA), Colombia (INVIMA), Argentina (ANMAT), Panama, El Salvador, Chile, Dominican Republic — different files. bioaccess® runs ISO 14155 architecture and in-country ethics plus national-regulator submissions in the jurisdictions we operate. Ask for a study-specific calendar.
bioaccess® still runs clinical trials in Colombia (Julio G. Martinez-Clark, 23 August 2026). INVIMA is a file a local entity manages — responses, ethics, investigational import, site activation — not a reason to take every new first-in-human out of the country. In-country CRO work there since 2010. If the protocol belongs in Colombia, we run it in Colombia.
Oversight distance
Published Australia comparison: ~14–20+ hours travel and a 14–18 hour time difference from the U.S. Latin America is same or adjacent U.S. time zones and short-haul flights. Quality is not the argument. The founder’s weekly calendar is.
Surgical volume
Australia’s population base is smaller; device-patient competition at sites is real. Latin America is where bioaccess® carries later patient-phase work on the same regional infrastructure. Volume belongs on the geography slide for implant EFS. Australia remains stronger on English end-to-end operations and — as we already say on the compare page — arguably the longest early-phase-to-global-pivotal track record in several modalities. Tendyne is one reason that sentence exists.
ISO 14155 and 21 CFR 812.28 are geography-neutral
Both shops should run device investigations to ISO 14155. bioaccess® packages English monitored data for eligibility under 21 CFR 812.28 (devices) or 21 CFR 312.120 (drugs). Acceptance is FDA’s, case by case. It is not awarded because the trial ran under CTN, and it is not denied because it ran under INVIMA or ANVISA. “Latin American device data doesn’t count” is folklore, not the regulation.
What counts is an inspection-ready TMF, source-verified CRFs, and a narrative that matches the Pre-Sub / IDE / 510(k) story. Mobius answers with ISO 9001 and ANZ-based data management (their FAQ ties Australian EDC/DM staff to R&DTI eligibility). bioaccess® answers with U.S. regulatory anchoring and the 812.28-ready data room on The First-in-Human CRO.
Who should hire which shop
Hire an Australia EFS CRO such as Mobius when you will form an eligible Australian company and the 43.5% offset is part of the financing; the protocol needs English ANZ investigators; the asset benefits from Australia’s EFS-to-pivotal track record (Tendyne-shaped structural work is the existence proof); or investors asked for an Australian R&D footprint by name — and you will fund Australian gross while any rebate arrives after lodgement.
Hire bioaccess® when the number that matters is gross cash this quarter and a 35–45% lower Latin American cash base (program experience; varies) beats a conditional recovery next tax year; you will not stand up an Australian entity for a first feasibility; you want U.S. time-zone oversight; the study needs Latin American surgical volume and later phases in the same region; or Colombia is the right INVIMA file. We still run those trials.
Decision table
| Row | Mobius (Australia EFS CRO) | bioaccess® (First-in-Human CRO) |
|---|---|---|
| Identity | Device-first ANZ boutique, 2008; ISO 9001; 140+ studies / 100+ devices (homepage) | FIH focus since 2010; U.S. anchor + LATAM execution; 50+ pre-qualified sites, 19 countries (published FIH page) |
| Public device proof | Tendyne AU EFS → pivotal; CE 2020, FDA 2025. NCT03406416 lead sponsor | U.S. device programs in LATAM; published case of an AU ethics decline that moved to El Salvador / Panama, Chile under evaluation |
| Start-up | CTN + HREC (~6–8 weeks typical) + site governance | Country ethics + INVIMA / ANVISA / ANMAT / others; ANMAT cap already published; no new median here |
| Gross cash | Higher AU base; their EFS band AUD $250k–$1M full-service | ~35–45% below AU on gross, program experience |
| Rebate | If you have an eligible AU entity; they help identify offsets | Not used; no AU entity |
| Language / continuity | English end-to-end; ANZ → U.S. office | English data room; Spanish/Portuguese sites; U.S. time zones |
| FDA foreign data | ISO 14155 → 21 CFR 812.28 (FDA decides) | ISO 14155 → 21 CFR 812.28 (FDA decides) |
One published bioaccess® fact sits next to “Australia always gets ethics”: a U.S. medical-device startup came to us after an Australian HREC declined its first-in-human. Committees decline for feasibility, insurance, and standard-of-care fit — not only safety. That program is activating in El Salvador and Panama, with Chile under evaluation. Geography is a contingency, not a religion.
Queries this page is meant to answer
- Mobius CRO / Mobius Medical CRO — who they are, what they published, when they are the right ANZ device shop.
- Australia EFS CRO / ANZ early feasibility CRO — CTN, HREC, ISO 14155, local sponsor, AUD $250k–$1M full-service band.
- Australia vs Latin America first-in-human device — gross cash 35–45% below AU; rebate only with an eligible entity; start-up broadly comparable once governance is counted.
Tax math: the rebate article. Country table: the compare page. Operating model: the First-in-Human CRO page, including the published FIH-12™ language (written protocol-to-LPLV clock; project-management and monitoring fees credited if we miss for reasons within our control; full terms in the proposal).
Frequently asked questions
Is Mobius Medical a good CRO for an Australian device EFS?
For an ANZ hospital implant or interventional early-feasibility study, yes — it belongs on a serious shortlist. Public record: ISO 9001, 2008 founding, North Sydney HQ, U.S. and New Zealand offices, 140+ / 100+ device studies on their homepage, Tendyne EFS-to-pivotal (CE 2020, FDA 2025), lead sponsor of NCT03406416. “Good” still depends on entity plan, cash, and whether ANZ is the right geography.
What does a full-service Australia EFS cost?
Mobius’s startup FAQ: typically AUD $250,000–$1 million full-service; pivotal higher. A band, not a quote. Gross, not net of R&DTI.
Is Australia cheaper than Latin America after the R&D tax incentive?
Only if you fully capture 43.5% through an eligible Australian company and fund the higher gross while you wait. On cash out the door, Latin America is typically 35–45% lower in bioaccess®’s program experience. After a fully captured rebate the gap is about 5–15%, and in some programs the rebate can close or reverse it. Details on the rebate math post.
Will FDA accept Latin American device data like Australian data?
Foreign clinical data from either region can support a U.S. device file when it meets 21 CFR 812.28 and ISO 14155 / GCP. Case by case. Not awarded for CTN. Not denied for INVIMA or ANVISA.
Does bioaccess® still run first-in-human trials in Colombia?
Yes. As of 23 August 2026 we still run clinical trials in Colombia. INVIMA clocks are managed in-country. Colombia is not a retired geography.
Next step
If the live question is “Mobius CRO or Latin America?”, bring the protocol outline, the IDE or 510(k) destination, and whether an Australian entity is actually in the legal workplan. We will put calendar and cash on one page — including Colombia when that is the right file — and we will not pretend the Tendyne history is irrelevant.
bioaccess® is the First-in-Human CRO. Book a 30-minute strategy call. Country table: bioaccess® vs Australia.